Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabazitaxel in dedifferentiated liposarcoma
NL-OMON45497Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in Liposarcoma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival at 12 weeks. Started Sep 2018; status: active, not recruiting.
02
Drugs
cabazitaxel
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NL-OMON45497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45497.